In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for the breast cancer community this week when it approved a new breast cancer therapeutic called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.Read More
Cancer treatments have been, and continue to be in most cases, based on the organ site where the tumor originates—some treatments are specific for breast cancer, some for lung cancer, and so on. However, rapid advances in genomic sequencing technologies have led to a recent development that deviates from the long-held notion of treating cancers based on the site of origin.Read More
In 2017, electronic cigarettes (e-cigarettes) were the most commonly used tobacco product among high and middle school students. Many public health experts believe that youth use of e-cigarettes has reached an epidemic proportion.
On September 12, 2018, the U.S. Food and Drug Administration (FDA) announced a series of critical and historic enforcement actions related to the sale and marketing of e-cigarettes to kids. This effort included issuing more than 1,300 warning letters and fines to retailers who illegally sold e-cigarette products to minors.Read More
The past month has seen the U.S. Food and Drug Administration (FDA) expand the use of four anticancer therapeutics, providing new treatment options for patients with four types of cancer. On Aug. 16, 2018, the agency approved the immunotherapeutic nivolumab (Opdivo) for treating certain patients with small cell lung cancer and approved the molecularly targeted therapeutic lenvatinib (Lenvima) for treating certain patients with the most common type of liver cancer, hepatocellular carcinoma.Read More
Today, the American Association for Cancer Research (AACR) released its eighth annual Cancer Progress Report. The report highlights how federally funded research that provides a deep understanding of the complexities of cancer is spurring advances across the clinical cancer care continuum and improving survival and quality of life for people around the world.Read More
Building upon the success of the African Cancer Researchers Travel Awards, the American Association for Cancer Research is pleased to announce the expansion of this award program and to invite eligible applicants from all low-, lower-middle, and middle-income economy countries (LMIC).Read More
As a predoctoral student in the Integrated Biomedical Sciences Graduate Program at The Ohio State University in 2005, Bethany Mundy-Bosse, PhD, had plans to focus her graduate work on basic stem cell biology to enhance and expand her previous research experience in this field. “When I first started working in a research lab, I was working with stem cells,” recalls Mundy-Bosse, “with every intention of continuing on with basic stem cell biology.” However, after attending a course in immunology with renowned physician-scientist Michael Caligiuri, MD, she found herself completely fascinated by this field. It was this course that would ultimately motivate her to shift her career focus toward tumor immunology.Read More
Immuno-oncology has revolutionized treatment for certain types of cancers, but currently it is only effective for about 20 percent of cancer patients. To drive the development of safe and effective immunotherapies for all patients, we need strong science at every stage of drug development, particularly in combination therapy. To this end, refining existing non-clinical models or developing new ones to assess the safety of immuno-oncology products will require cross-sector collaboration among regulatory, industry, and academic experts. The upcoming FDA-AACR Non-clinical Models for Safety Assessment of Immuno-oncology Products Workshop will bring these stakeholders together to discuss this vital issue.Read More
The American Association for Cancer Research (AACR) began publishing scientific articles in 1916, and now proudly publishes eight peer-reviewed journals which cover a diverse array of cancer-related topics. The editors …Read More
AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) recently hit another milestone: the public release of a fourth dataset, which comes on the heels of three prior public data releases, an expansion of the number of participating institutions, and a recent publication, which was among the most read articles in JCO Clinical Cancer Informatics in July, according to the publisher.Read More
Anthracyclines, a widely used class of chemotherapeutics, work in several ways to kill rapidly dividing cells, including those found in a tumor. While these drugs are commonly used to treat many types of adult and childhood cancer, they have a detrimental side effect – cardiotoxicity.
The cardiotoxicity of anthracyclines is dose-dependent; the more exposure patients have to the drug, the more serious risk they carry for heart-related problems. This can represent a unique challenge in children treated with anthracyclines, whose hearts are still developing.Read More